Question 1

What is Tesamorelin?

Accepted Answer

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino acid GHRH sequence with a trans-3-hexenoic acid modification at the N-terminus. It acts as a GHRH receptor agonist on pituitary somatotroph cells and received FDA approval in 2010 as Egrifta for HIV-associated lipodystrophy. Tesamorelin represents one of the most clinically characterized GHRH analogs in published research. It is available for in vitro research use only outside of FDA-approved clinical application.

Question 2

How does Tesamorelin work in research models?

Accepted Answer

In research models, Tesamorelin binds the GHRH receptor on pituitary somatotroph cells, activating Gs protein coupling and cAMP-PKA signaling that drives GH gene transcription and secretory vesicle release. The N-terminal modification provides DPP-IV resistance extending stability relative to native GHRH. Downstream IGF-1 axis increases and published body composition changes including visceral adipose reduction are documented in published clinical trial data. See /how-tesamorelin-works/ for the complete mechanism overview.

Question 3

What has Tesamorelin been studied for in published research?

Accepted Answer

Published research has examined Tesamorelin in clinical pharmacokinetics and pharmacodynamics (GH pulsatility characterization), Phase III trials for HIV lipodystrophy (visceral adipose tissue reduction), IGF-1 axis response studies, body composition research using DEXA and MRI methodology, and GHRH receptor pharmacology characterization. The FDA approval data package represents one of the most comprehensive published evidence bases for any GH secretagogue.

Question 4

What is Tesamorelin's half-life in research models?

Accepted Answer

Published pharmacokinetic studies have characterized Tesamorelin with a plasma half-life of approximately 26 minutes following subcutaneous administration in human clinical studies, substantially extended compared to native GHRH which has a half-life of minutes. The trans-3-hexenoic acid modification provides resistance to DPP-IV cleavage at the N-terminal alanine, which is the primary native GHRH degradation mechanism. This extended stability is the primary pharmacokinetic advantage documented in published comparative studies.

Question 5

How is Tesamorelin stored for research use?

Accepted Answer

Research-grade Tesamorelin should be stored as lyophilized powder at 2 to 8 degrees Celsius or at -20 degrees Celsius for long-term storage, following storage conditions established in published clinical formulation documentation. The commercial Egrifta formulation provides a reference for stability parameters. Reconstituted solutions should be used within the timeframe specified by the supplier consistent with published clinical methodology.

Question 6

What purity standard should research-grade Tesamorelin meet?

Accepted Answer

Research-grade Tesamorelin should meet at least 98% purity by HPLC analysis with mass spectrometry confirmation of the 44-amino acid plus N-terminal modification molecular weight. Certificate of Analysis should confirm the trans-3-hexenoic acid modification through mass spectrometry characterization. Sequence verification of all 44 residues should be confirmed through COA documentation before in vitro use.

Question 7

What did the Phase III trials establish about Tesamorelin?

Accepted Answer

Published Phase III clinical trials of Tesamorelin in HIV lipodystrophy patients documented significant reductions in visceral adipose tissue measured by MRI cross-sectional area analysis at 26 weeks relative to placebo. Secondary published endpoints included IGF-1 increases, triglyceride changes, and quality of life measures. These Phase III data supported the 2010 FDA approval and are publicly available through published journal articles and FDA regulatory documentation.

Question 8

Is Tesamorelin water soluble?

Accepted Answer

Tesamorelin is water soluble and is formulated in aqueous vehicle for clinical injection, as documented in the Egrifta prescribing information. Research-grade Tesamorelin is typically reconstituted in sterile water or saline for preclinical research applications. The 44-amino acid peptide has good aqueous solubility at physiological pH conditions.

Question 9

How has Tesamorelin been studied in visceral adipose tissue research?

Accepted Answer

Published clinical research has used MRI cross-sectional visceral adipose area measurement as the primary endpoint for Tesamorelin body composition research. Phase III trials documented significant reduction in trunk and visceral fat in HIV lipodystrophy patients. Researchers have also examined metabolic biomarker changes including triglycerides and adiponectin as secondary endpoints. The published MRI-based methodology from these trials represents an established approach for visceral adipose research.

Question 10

How does Tesamorelin compare to CJC-1295 in published GH secretagogue research?

Accepted Answer

Tesamorelin and CJC-1295 both act as GHRH receptor agonists with extended stability relative to native GHRH but with different modification approaches. Tesamorelin has the larger published evidence base due to its FDA approval pathway including Phase III clinical trials. CJC-1295 research has focused more on pharmacokinetic characterization with fewer large-scale clinical publications. Both compounds are studied in GH pulsatility research, with tesamorelin providing more clinical reference data for protocol design.

Question 11

Where can researchers source Tesamorelin for in vitro research?

Accepted Answer

Research-grade Tesamorelin for in vitro use is available from Spartan Peptides with at least 98% HPLC-verified purity and Certificate of Analysis documentation confirming N-terminal modification. All Tesamorelin is for in vitro research use only. Researchers should source from suppliers confirming the specific N-terminal trans-3-hexenoic acid modification in COA mass spectrometry data, as this modification is essential to the stability profile of the compound.

GLP-3(Reta) | Triple-Agonist Metabolic Research

NAD+ 750mg | Cellular Energy & DNA Repair Research

MOTS-c | Mitochondrial Metabolism Research Peptide

BPC-157 5mg | Tissue Repair & Gut Health Research

Tesamorelin Frequently Asked Questions

Explore Full Research Index